作者: Jéssica Gomes , Marcelo Cruz
DOI: 10.2147/OTT.S75388
关键词:
摘要: Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have shown effectiveness for advanced non-small-cell lung cancer (NSCLC) with activating mutations in EGFR gene. However, resistance to TKIs develops mostly secondary T790M mutation exon 20. The use of afatinib associated cetuximab represents a new possibility therapy following progression on gefitinib or erlotinib. We present two patients who acquired first-generation TKI and underwent combination treatment plus as third-line therapy. Both presented partial response, time duration disease control was 8 months 10 months. combined emerges NSCLC harboring mutated after consequently TKIs. Further studies are necessary consolidate data.